## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.5% below STRENGTH zone (3.0-6.0%); PEG 1.30 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($310.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. UnitedHealth Group commits to improvements after independent audit, patient backlash**
- Source: CNBC | 20251219T124212 | Neutral | Relevance: 100%
- UnitedHealth Group has released the initial findings from an independent audit of its business practices, committing to 23 "action plans" to implement recommended improvements by March of next year. The audit focuses on Medicare Advantage programs and pharmacy benefit manager practices, aiming to rebuild patient trust amid previous backlash and investigations. Despite findings indicating "generally sound" policies, recommendations were made for enhancement, such as strengthening resolution processes for non-payment cases.

**2. UnitedHealth exits South America with Banmedica sale**
- Source: MSN | 20251217T190442 | Bearish | Relevance: 100%
- UnitedHealth has announced its complete exit from the South American market by selling its Chilean health business, Banmedica. The sale marks a strategic shift for the U.S. healthcare giant, divesting its remaining operations in the region.

**3. UnitedHealth Group outlines action plans for operational improvement following independent audits**
- Source: Fierce Healthcare | 20251219T180903 | Somewhat-Bullish | Relevance: 100%
- UnitedHealth Group has outlined 23 action plans to improve operations across its business lines following independent audits into its processes. These audits, conducted by FTI Consulting Inc. and Analysis Group Inc., focused on risk assessments in Medicare Advantage, care services management at UnitedHealthcare, and Optum Rx's drug manufacturer discount policies. The company expects all improvements to be complete by the end of Q1 2026, aiming for greater transparency and continuous improvement.

**4. MFG Wealth Management Inc. Invests $2.26 Million in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251219T120851 | Somewhat-Bullish | Relevance: 100%
- MFG Wealth Management Inc. has acquired a new position in UnitedHealth Group (UNH) during the third quarter, purchasing 6,552 shares valued at approximately $2.26 million. This investment accounts for 1.7% of MFG Wealth Management Inc.'s portfolio. UnitedHealth Group reported strong Q3 earnings, exceeding analyst expectations, with revenues up 12.2% year-over-year.

**5. Country Club Bank Sells 12,406 Shares of UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251219T092151 | Somewhat-Bullish | Relevance: 100%
- Country Club Bank significantly reduced its stake in UnitedHealth Group (NYSE: UNH), selling 12,406 shares in Q3, bringing its total holdings to 6,161 shares valued at $2.127 million. Despite this, institutional ownership remains high at 87.86%, with several other firms increasing their positions. UnitedHealth Group reported strong Q3 earnings, beating analyst estimates, and maintains a consensus "Hold" rating with an average target price of $385.54.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 38 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 7.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.30 suggests fair value with growth premium. Forward P/E 18.4x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $296.6B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.30 |
| Forward P/E | 18.4 |
| Current P/E | 20.0 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.7% to -1.5% (-6.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.5pp (needs >3.0% for momentum thesis). Below SMA200 (0.92x), long-term trend not supportive. RSI neutral at 47. OFD pattern: -DUH (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.46% (CS: 28) | Neutral |
| RSI_14 | 46.6 | Neutral |
| MACD Histogram | 0.45 | Bullish |
| vs SMA20 | 0.993x | Below |
| vs SMA50 | 0.970x | Below |
| vs SMA200 | 0.922x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $327.36
- **Stop Loss:** $310.02 (5.3% risk)
- **Target:** $344.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 69
- **Position Value:** $22,587.84
- **Portfolio %:** 22.59%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*